Thomas E. Witzig
Biogen Idec
8 Papers
64 Citations
Thomas E. Witzig is an academic researcher from Biogen Idec. The author has contributed to research in topics: Radioimmunotherapy & Ibritumomab tiuxetan. The author has an hindex of 3, co-authored 8 publications. Previous affiliations of Thomas E. Witzig include Northwestern University & University of Nebraska–Lincoln.
Chat about Author
Papers
Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Patients Treated With Ibritumomab Tiuxetan Radioimmunotherapy
Myron S. Czuczman,Christos Emmanouilides,Mohamed Darif,Thomas E. Witzig,Leo I. Gordon,Stephen Revell,Katie Vo,Arturo Molina +7 more
TL;DR: Analysis of data from patients in registration and compassionate-use trials suggests that the annualized incidences of t-MDS and t-AML are consistent with that expected in patients with NHL who have had extensive previous chemotherapy treatment and do not appear to be increased after treatment with the ibritumomab tiuxetan regimen.
148
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma.
Leo I. Gordon,Thomas E. Witzig,G. A. Wiseman,Ian W. Flinn,Stewart Spies,Daniel H.S. Silverman,Christos Emmanuolides,Larry Cripe,Mansoor N. Saleh,Myron S. Czuczman,Teresa Olejnik,Christine A. White,Antonio J. Grillo-Lopez +12 more
TL;DR: Data on the use of radiolabeled monoclonal antibodies directed against the CD20 antigen on malignant B cells is reviewed and the questions of long-term toxicity (late effects) are addressed.
65
Radioimmunotherapy of Relapsed Non-Hodgkin's Lymphoma with Zevalin, a 9~ Anti-CD20 Monoclonal Antibody 1
Gregory A. Wiseman,C.A. White,Thomas E. Witzig,Leo I. Gordon,Christos Emmanouilides,Andrew Raubitschek,Nalini Janakiraman,John Gutheil,Russell J. Schilder,Stewart Spies,Daniel H.S. Silverman,Antonio J. Grillo-L +11 more
- 01 Jan 1999
TL;DR: The chimeric monoclonal antibody Rituximab has now been approved by the United States Food and Drug Administration as a treatment for patients with relapsed or refractory, low-grade or follicular, B-cell NHL.
1
Safety o f Y ttrium-90 I britumomab T iuxetan Radioimmunothera py f or R elapsed L ow-Grade, F ollicular, o r Transformed N on-Hodgkin's L ymphoma
Thomas E. Witzig,C.A. White,Leo I. Gordon,Gregory A. Wiseman,Christos Emmanouilides,James L. Murray,John Lister,Pratik S. Multani +7 more
- 01 Jan 2003
TL;DR: Single-dose 90 Y ibritumomab tiuxetan RIT has an acceptable safety profile in relapsed NHL patients with less than 25% lymphoma marrow involvement, adequate marrow reserve, platelets greater than 100,000 cells/L, and neutrophils greater than 1,500 cells/ L.